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OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general
population and those with a mental health condition in the metropolitan area of São Paulo, Brazil.
METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using
the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally,
participants were asked if they had taken any medication in the previous 12 months for the treatment of any
mental health condition.
RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among
subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been
diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that
had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals
aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders
(10%), and those that used psychiatric services (29.8%) also reported higher use.
CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which
will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health
condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the
elderly had high benzodiazepine use, so careful management in these groups is required.
KEYWORDS: Psychiatry; Pharmacy; Psychotropic Drugs; Hypnotics and Sedatives; Benzodiazepines.
’ INTRODUCTION
Since its introduction in the early 60s (1), benzodiazepines
(BZDs) have been the most prescribed psychotropic medica-
tion worldwide (2), despite their various therapeutic and
side effects (2,3). Therapeutic indications for the use of BZDs
are diverse and include the treatment of seizures (4), alcohol
and barbiturate withdrawal symptoms (5), psychomotor
agitation (6), insomnia and other sleep disorders (7), panic
disorders (8), social phobia, generalized anxiety disorder (9),
and as an adjunctive treatment for both depression and mania
(10). Common side effects of BZD are drowsiness associated
with incoordination or ataxia, which may lead to car acci-
dents, problems with operating machinery, and, especially
among the elderly, falls (11). Memory impairments that are
potentially non-reversible have also been observed (3,12).
Long-term use of BZDs is related to physical dependence. Dis-
continuation from chronic BZD use can result in withdrawal
syndrome, particularly among the elderly (10). Withdrawal
symptoms that have been reported include anxiety, sleep
disturbance, irritability, a hand tremor, and rarely, more severe
conditions such as seizures and psychosis (13).
Current guidelines such as the National Institute of Health
and Care Excellence (NICE) (14) recommend that BZD should
be used at the lowest possible dose for the shortest period
possible. There are considerable evidence-based concerns
regarding the serious adverse consequences of BZD use, such
as falls (14), risk of suicide, abuse, dependence (10), and risk of
Alzheimer’s disease (15). In a series of pharmacoepidemiolo-
gical studies conducted by the World Mental Health Survey
Initiative (WMHS) (16,17), the use of psychotropic agents was
evaluated in the general population. In addition, if a res-
pondent had been diagnosed with a psychiatric disorder in the
12 months preceding the survey, this was recorded (18,19). The
observed prevalence of BZD use in the general population
ranged between 3.2% and 18.6% (Table 1). These rates were
even higher among individuals that had been diagnosed with a
psychiatric disorder, with a range between 9.2% and 41.9%.
Generally, the prevalence of BZD use was higher among sub-
jects with a mood disorder as opposed to an anxiety disorder.DOI: 10.6061/clinics/2020/e1610
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High consumption of BZD was also observed among females
and older people (16,17,18,19,20). However, methodological
diversity hampered a direct comparison of the rate of BZD use
among participant countries of the WMHS Initiative.
Several studies on BZD use have been conducted in the
non-developed regions. In Chile, the estimated prevalence of
BZD use in the general population was 4% (21) (Table 1).
Few studies have been conducted on the prevalence of BZD
use in Brazil (20). The relationship between BZD use and
mental health disorders in the general population has rarely
been investigated (22). The reported prevalence of BZD use
over one month in the general population was 2% and 3% in
Rio de Janeiro and São Paulo, respectively (23). Among
individuals who had been diagnosed with a mental health
disorder, the one-month prevalence of BZD use was lower in
Rio de Janeiro than in São Paulo (3.4% vs. 7.1%, respectively).
However, the methodological differences regarding the
period investigated, sample characteristics, and data collec-
tion preclude any direct comparisons being made (20). There
is a lack of knowledge regarding the use of BZDs over a
period longer than 12-months, its monotherapy or poly-
pharmacy patterns, the prevalence of BZD use in specific
mental health disorders, and the impact of BZD use on
symptom severity, comorbidities, health insurance coverage,
and health service use.
Given the scarcity of epidemiological data, we aimed to
report the prevalence of BZD use in a representative sample
of the general population and those with a mental health
condition (diagnosed in the last 12 months) in São Paulo,
Brazil. Information about monotherapy and the combined
use of BZDs along with its relationship to symptom severity,
comorbidities, health insurance coverage, and health service
use are also discussed.
’ METHODS
São Paulo Megacity Mental Health Survey
Data for this report were sourced from the São Paulo
Megacity Mental Health Survey (SPMHS). The SPMHS is the
Brazilian segment of the World Mental Health Survey
Initiative, coordinated by the World Health Organization
and Harvard University. It was conducted in more than 28
research centers around the world. The SPMHS is a cross-
sectional, population-based study. It was designed to
estimate the prevalence of mental health disorders, mental
health services, and psychotropic drug utilization in a
representative sample of the general population. By design,
individuals over 18 years old, living in the São Paulo
metropolitan area were interviewed by trained lay inter-
viewers (24).
Sample
A sample of 5,037 individuals (response rate: 81.3%) were
assessed using the Composite International Diagnostic
Interview (CIDI), which generates DSM-IV diagnoses. We
report on a subsample of 2,935 subjects who were submitted
to a more extended version of the interview, which included
questions on psychotropic drug use (24).
Data collection
Participants were asked about prescription medicines that
they had used in the previous 12 months for emotional
issues, nerves, mental health, substance use, energy, con-
centration, sleep, or stress. According to the Anatomical
Therapeutic Chemical (ATC) index 2018 (https://www.
whocc.no/atc_ddd_index/), the medicines focused on in
this report were anxiolytics (alprazolam, bromazepam,
clobazam, chlordiazepoxide, cloxazolam, diazepam, and
lorazepam), hypnotics and sedatives (chloral hydrate,
flunitrazepam midazolam, zolpidem), and antiepileptics
(clonazepam). The term ‘‘benzodiazepines’’ (BZDs) will be
used henceforth to refer to all the above medicines.
Data analysis
The data analysis examined both the prevalence of BZD
use in the general population and among individuals who
had been diagnosed with a mental health disorder. Diag-
nostic categories included in the analysis were anxiety,
mood, substance use, and impulse-control disorders. Other
clinical information included in the analysis was related to
comorbidities and symptom severity.
Socio-demographic information collected included age,
sex, education, family income, marital status, and employ-
ment status. Information about service use and health
insurance was also analyzed.
The factors associated with BZD use were explored
through a logistic regression analysis. The data analysis
was performed using Statistical Analysis System (SAS).
’ RESULTS
The prevalence of BZD use in the general population in the
previous year was 3.6%. Diazepam (1.3%) and clonazepam
(0.8%) were the most frequently used BZDs. Females used










Alonso et al. (25) Europe 2001-2003 ESEMeDa 21,425 X18 9.8% 25.5%
Bruffaertes et al. (16) Belgium 2001-2002 ESEMeDa 2,419 X18 12.3% 25.5%
Codony et al. (18) Spain 2001-2002 ESEMeDa 5,473 X18 11.4% 32.7%
Campanha et al. (20) Brazil 2005-2007 SPMHSb 2,935 X18 3.6% 7.8%
Gasquet et al. (17) France 2001-2003 ESEMeDa 2,894 X18 18.6% 41.9%
Grinshpoon et al. (19) Israel 2003-2004 INHSc 4,859 X21 3.2% 9.2%
Other studies in South America
Rojas et al. (21) Chile 1996-1998 3,870 16-64 04% -
Quintana et al. (22) Rio de Janeiro 2007-2008 1,208 X15 1.6% 3.4%
Quintana et al. (23) São Paulo 2007 2,536 15-75 2.7% 7.1%
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BZDs more often than males (5.5% vs. 1.6%). The use of BZD
was also higher among subjects aged over 65, compared to
those aged 50-64 and 18-24 years (7.8% vs. 6.1% vs. 1.8%,
respectively) (Table 2).
The use of BZD monotherapy was reported in 1.8% of the
sample. Antidepressants (1.4%) were the most commonly used
psychiatric medication in combination with BZD (Table 3).
Table 4 presents the correlates of BZD use according to the
socio-demographic variables, psychiatric diagnoses, comor-
bidities, symptom severity, use of health services, and the
possession of private health insurance coverage.
The use of BZD was higher in those aged between 35-49
years (10.2% vs. 4.7%; OR=2.3; 95%CI=1.1-4.7), and over 50
years (11.1% vs. 4.7%; OR=2.6; 95%CI=1.2-5.3), than those
between 18-34 years (4.7%). The use of BZDs was also higher
among homemakers, retired subjects, and the unemployed
compared to employed individuals (11.8% vs. 10.1% vs. 5.9%,
respectively (Table 4).
Concerning psychiatric disorders, individuals diagnosed
with a mood disorder (14.7%; OR=5.7; 95%CI=2.5-13), anxi-
ety disorder (8.1%; OR=3.5; 95% CI=1.6-7.8), or substance use
disorder (7.9%; OR=2.9; 95%CI=1.5-5.7) were more likely to
use BZD than those without these disorders (Table 4).
Psychiatric comorbidities and symptom severity also play
a role in the use of BZDs. Although individuals who had
been diagnosed with two or more disorders used more BZDs
than those with a single diagnosis (11.2% vs. 5.6%; OR=2.1,
95%CI=1.3-3.5), the likelihood of using BZD was lower in the
adjusted model 2 (OR=0.4; 95%CI=0.2-0.9). The likelihood
of BZD use was higher among patients with disorders
that were considered to be serious or moderate than among
those with a mild disorder (10.0% vs. 3.7%; OR = 2.8; 95%CI=
1.7-4.8) (Table 4).
There was a trend (p = 0.0505) of higher BZD use among
individuals who had health insurance coverage than those
who did not (10.7% vs. 6.1%; OR=1.9; 95%CI=1.0-3.4). Remark-
ably, BZD use among individuals who reported using psychi-
atric services was almost 30 times higher than those who did
not (29.8% vs. 1.3%; OR=25.0; 95%CI=13.7-45.6) (Table 4).
BZD use among subjects who had been diagnosed with
a mental health disorder was 7.8%. Among the diagnostic
classes, mood disorders displayed the highest prevalence of
BZD use (14.7%). Participants who had been diagnosed with
a panic disorder or bipolar disorder (33.7% and 23.3%,
respectively) reported using BZD the most (Table 5).
The likelihood of BZD use was also higher among those
with obsessive-compulsive disorder (OR=7.0; 95%CI=1.6-
30.0), drug abuse (OR=8.2; 95%CI=1.9-36.4), drug dependence
(OR=9.3, 95%CI=1.5-58.8), impulse control disorders (OR=5.6,
95%CI=1.1-27.7), and attention deficit disorder (OR=17.5, 95%
CI=2.1-146.8) (Table 5).
Subjects that had not been diagnosed with a mental health
disorder reported infrequent BZD use (1.9%). This preva-
lence was much higher among females than males (OR=13.0;
95%CI=4.1-41.3) (Table 5).
Considering the number of psychotropics used, 3% of
subjects that had been diagnosed with a mental health dis-
order reported using BZD as a monotherapy. This was most
frequent in those who had been diagnosed with attention
deficit disorder (10.1%). The mean frequency of monother-
apy was 2.9% for anxiety disorders, and 9.8% for panic dis-
orders. Lower rates of BZD use were observed among
individuals with mood (4%), bipolar I/II (4.5%) or major
depressive disorders (4%) (Table 5).
’ DISCUSSION
The 12-month prevalence of BZD use in the São Paulo metro-
politan area was 3.6%. This rate is similar to that reported in
a survey conducted in Rio de Janeiro (22). Similarly, in Chile,
about 4% of individuals reported using hypnotics and anxio-
lytics (21). Conversely, the reported prevalence of BZD use in
European countries (9.8% (25), 12.3% (16), 5.5% (19)), and the
United States of America (5.2% (26)) is higher.
Even though the methodologies used were different,
several studies have reported higher BZD use in Brazil
previously. In 1979, the reported use of BZDs in São Paulo
was 8.8% (27). Additionally, in 1993, 8.0% used tranquilizers
and 1.2% used hypnotics (28). Recent studies have shown
that the prevalence of use has indeed decreased to 1.6% and
2.7%, respectively, in Rio de Janeiro (22) and São Paulo (23).
The higher prevalence of BZD use among females may
be due to females having a higher rate of mental health dis-
orders, such as anxiety, major depression, and dysthymia (24).
This sex difference persists even among individuals with a
Table 3 - Prevalence of monotherapy and combined use of benzodiazepines in the previous 12 months in the general population by
sex. São Paulo Megacity Mental Health Survey (N=2935).
N (%) SE OR (95% CI) female/male X2 p-value
Benzodiazepinesa 162 (3.6) 0.5 3.7 (2.0-6.7) 18.2 o0.0001
Monotherapyb 65 (1.8) 0.4 3.6 (2.0-6.5) 18.5 o0.0001
Combined usec
Benzodiazepines +antidepressant 79 (1.4) 0.2 6.2 (2.3-16.7) 13.3 0.0003
Benzodiazepines + antipsychotics 11 (0.2) 0.1 11.3 (2.7-48.0) 10.9 0.001
Benzodiazepines + mood stabilizer 20 (0.4) 0.1 1.5 (0.5-5.2) 0.5 0.4904
Weighted proportions. OR, odds ratio; CI, confidence interval. aAt least one psychotropic drug. bOnly benzodiazepines. cAny benzodiazepine drug plus
another psychiatric medication. Sex comparison: males were used as the reference group.
Table 2 - Prevalence of benzodiazepine use in the previous
12 months in the general population according to sex and age.
São Paulo Megacity Mental Health Survey (N=2935).
Sex N (%) SE p-value
Total 162 (3.6) 0.5 0.0004
Female (N=1697) 122 (5.5) 0.9
Male (N=1238) 40 (1.6) 0.3
Age 0.0687
18-24 (N=406) 09 (1.8) 0.9
25-34 (N=684) 18 (2.6) 0.7
35-49 (N=1,026) 68 (3.4) 0.6
50-64 (N=590) 48 (6.1) 1.4
X65 (N=229) 19 (7.8) 3.5
Weighted proportions.
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psychiatric diagnosis and among those without any psychiatric
diagnosis. This suggests that other factors might be involved.
Accordingly, the higher use of psychotropic drugs by females
could also be explained by treatment-seeking behavior and
lower alcohol and psychotropic drug use (25).
People working at home and those with low social func-
tioning, such as retirees and the unemployed, also reported
higher BZD use. This is in line with previous reports in
Europe (29). In the current study, the use of psychiatric
services increased the chance of using BZDs by 30%. Seeking
help for emotional problems appears to be associated with
the use of BZDs (29).
A surprising finding is the higher use of BZD among those
subjects who had been diagnosed with a mood disorder
compared to those with an anxiety disorder (14.7% vs. 8.1%,
respectively), even regarding monotherapy (4.0% vs. 2.9%).
However, this finding has been reported in a number
of studies that have used a similar methodology (16). Some-
times, the use of BZDs among subjects with mood dis-
orders has been comparable (16) or higher than the use
of antidepressants (18,29). The non-specific effects of BZD
appear to be less harmful than first-line antidepres-
sants, which has prompted some clinicians to prefer BZD
(10). In France, the use of hypnotics and anxiolytics was
similar for those with depression or an anxiety disorder
(43.4% vs. 42.5%). This finding reflects the challenges
in diagnosing and managing mood disorders in primary
care (17).
Table 4 - Correlates of benzodiazepine use in the previous 12 months with sociodemographic variables, mental health disorders,
disorder severity, comorbidities, use of health services, and the existence of private health insurance coverage. São Paulo Megacity
Mental Health Survey (N=1,271).
Model 1 Model 2
Variable Total sample N (%) OR (95% CI) p-value OR (95% CI) p-value
Sex
Female 836 85 (8.7) 1.5 (0.7-3.2) 0.3563
Male 435 32 (6.2) 1
Age (years) 0.0418
18-34 481 20 (4.7) 1
35-49 472 56 (10.2) 2.3 (1.1-4.7) 0.0197
X50 318 41 (11.1) 2.6 (1.2-5.3) 0.0127
Education (years) 0.4799
Low (0-4) 346 36 (9.5) 1.3 (0.7-2.4) 0.421
Low-average (5-8) 330 28 (6.8) 0.9 (0.5-1.8) 0.7639
High-average/high (X9) 595 53 (7.5) 1
Family income 0.3014
Low (p0,5) 344 18 (5.5) 0.5 (0.2-1.0) 0.0641
Low-average (0.5-1.0) 344 34 (7.5) 0.7 (0.37-1.2) 0.1714
High-average (1.0-2.0) 292 30 (7.6) 0.7 (0.4-1.3) 0.2091
High (42.0) 291 35 (10.9) 1
Marital status
Married/cohabiting 777 80 (8.7) 1
Previously married/Never married 494 37 (6.7) 0.8 (0.5-1.2) 0.2566
Employment status 0.0058
Employed/student 729 58 (5.9) 1
Homemaker/retired 331 42 (11.8) 2.2 (1.4-3.5) 0.0014
Unemployed 211 17 (10.1) 1,8 (0.8-4.4) 0.1839
Anxiety disorder
No 435 28 (7.3) 1 1
Yes 836 89 (8.1) 1.1 (0.7-1.7) 0.585 3.5 (1.6-7.8) 0.0019
Mood disorder
No 704 35 (3.2) 1 1
Yes 567 82 (14.7) 5.2 (2.6-10.3) o0.0001 5.7 (2.5-13.0) o0.0001
SUDa
No 1108 104 (7.8) 1 1
Yes 163 13 (7.9) 1.0 (0.5-2.1) 0.984 2.9 (1.5-5.7) 0.0019
ICDb
No 1080 101 (8.2) 1
Yes 191 16 (5.8) 0.7 (0.4-1.3) 0.2634
Comorbidity
No 731 48 (5.6) 1 1
Yes 540 69 (11.2) 2.1 (1.3-3.5) 0.0035 0.4 (0.2-1.0) 0.0255
Severity
Mild 397 19 (3.7) 1
Serious/Moderate 874 98 (10.0) 2.8 (1.7-4.8) 0.0001
Service use
No 935 15 (1.3) 1 1
Yes 336 102 (29.8) 31.2 (19,3-50.4) o0.0001 25.0 (13.7-45.6) o0.0001
Health insurance
No 798 56 (6.1) 1
Yes 473 61 (10.7) 1.9 (1.0-3.4) 0.0505
Weighted proportions. OR, odds ratio; CI, confidence interval. aSubstance use disorders. bImpulse control disorders. Model 1: crude. Model 2: All variables
were analyzed together.
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There was also increased use of BZDs in patients with
more severe psychiatric disorders. One explanation for this
could be the prescribing habits of clinicians. Usually, clini-
cians might include an adjunctive medication, such as BZD,
for non-responders to treat residual symptoms such as inso-
mnia and anxiety.
BZD is not considered to be the first-line treatment for
most anxiety disorders, such as generalized anxiety disorder,
phobias, and post-traumatic stress disorder, with antidepres-
sants and antiepileptic drugs, usually prescribed (14).
Nevertheless, the use of BZDs was also higher (18,25,29) or
similar to the use of antidepressants among individuals with
an anxiety disorder (16). It appears that in Brazil, patients are
not receiving the most appropriate treatment option (22)
because the use of BZD as a monotherapy was higher than
that of other classes of psychotropic medications among
subjects who had been diagnosed with an anxiety disorder.
General practitioners issued 46.9% of the BZD prescriptions
(28). Other specialists, such as cardiologists (15.3%) and
neurologists (4.5%), issued more tranquilizer prescriptions
than psychiatrists (11.7%).
The reported higher use of BZD in the elderly is in line
with the patterns observed in most studies conducted in the
United States of America (26), Canada (30), and Europe (25).
In a systematic review (31) on inappropriate prescriptions
for long-term BZD use and analogous non-BZD z-drugs,
psychological dependence, absence of social support, ignor-
ance about treatment options, withdrawal symptoms, and
unfamiliarity with the potential side effects were the main
drivers that perpetuate their use. Additionally, previous use
was one of the main factors associated with the likelihood of
BZD use among older patients (32). People from older
cohorts that have been extensively exposed to BZD in their
youth may become addicted (32), and become chronic users
(32). Other factors included chronic illness, stress, pain, and
insomnia (26). The higher BZD use in older cohorts is
concerning due to older individuals being more at risk of
falls (33,34,35), associated with healthcare utilization and
decline in functional status (36). The causative effect of BZD
on the risk of dementia is also a major concern (37). The
literature suggests that long-term exposure to BZD is
associated with an increased risk of Alzheimer’s disease
(38,15), without stringent confirmation (39).
Taken together, our data and the existing literature must
be urgently reviewed by governments, policymakers, and
medical societies. There is some consensus that BZD should
be discontinued in subjects aged 65 years or older. The most
recommended deprescribing strategy for long-term BZD and
Z-drug use is pharmacologic interventions. Multidisciplinary
reduction of BZD and Z-drug exposure with the addition of
alternative pharmacological therapies, psychological thera-
pies (anxiety management, stress management, and psy-
chotherapy), mixed programs (psychological therapy,
gradual dose reduction, and usual care), and psychological
education are some of the recommended approaches. These
interventions present numerous, heterogeneous, and poorly
described results, suggesting that studies are needed on how
to best deprescribe BZD and Z-drugs in the future (40).
’ CONCLUSION
According to the findings in the current study, the use of
hypnotics and sedatives, which are mostly composed of
BZD, has been declining over the last few decades in Brazil.
Those that were older, female, or had lower social function-
ing tended to have higher BZD use. Subjects diagnosed with
a mood disorder were more likely to use BZDs than those
with an anxiety disorder. Individuals with disorders that
were considered to be moderate or severe, those that used
psychiatric services, and those with health insurance cover-
age tended to have higher BZD use. It is a public health
challenge to find a surrogate for BZD and manage the
existing chronic users.
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